NCT01499420View on ClinicalTrials.gov

A Single Ascending Dose Study Examining the Safety and Pharmacokinetic Profile of Reconstituted High Density Lipoprotein (CSL112) Administered to Patients

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

December 31, 2012

Study Completion Date

March 31, 2013

Conditions

Stable Atherothrombotic Disease

Interventions

BIOLOGICAL

CSL112 (reconstituted high density lipoprotein)

Single escalating intravenous doses of CSL112

BIOLOGICAL

Placebo

Single intravenous doses of normal saline (0.9%)

Trial Locations (11)

19104

Study Site, Philadelphia

21215

Study Site, Baltimore

27710

Study Site, Durham

32209

Study Site, Jacksonville

33126

Study Site, Miami

40536

Study Site, Lexington

42431

Study Site, Madisonville

49770

Study Site, Petoskey

57701

Study Site, Rapid City

91911

Study Site, Chula Vista

04210

Study Site, Auburn

All Listed Sponsors

lead

CSL Limited

INDUSTRY

NCT01499420 - A Single Ascending Dose Study Examining the Safety and Pharmacokinetic Profile of Reconstituted High Density Lipoprotein (CSL112) Administered to Patients | Biotech Hunter | Biotech Hunter